Abstract
SAT131 - Pharmacokinetic (PK) and pharmacodynamics (PD) of BIO89-100, a novel glycoPEGylated FGF21, in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have